Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01312)
Name
Ozenoxacin
Synonyms    Click to Show/Hide the Synonyms of This API
Ozenoxacin; 245765-41-7; Xepi; T-3912; UNII-V0LH498RFO; T 3912; V0LH498RFO; 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic acid; GF-001001-00; Ozenoxacin Cream; Ozenoxacin [INN:JAN]; Ozadub; Xepi (TN); Ozenoxacin; T-3912; Ozenoxacin (JAN/USAN/INN); SCHEMBL1711829; CHEMBL3990047; GTPL10841; DTXSID00947446; CHEBI:136050; BCP16621; EX-A2693; WHO 8788; ZINC1483896; s6582; AKOS032947315; DB12924; SB16801; NCGC00532517-01; 1-Cyclopropyl-8-methyl-7-[5-methyl-6-(methylimino)-1,6-dihydropyridin-3-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; BS-16742; DA-31712; HY-14957; CS-0003657; FT-0701296; T3912; D09544; Q17125399; GF-001001-00; M-5120; T-3912; GF-00100100;T3912;T 3912; 1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)pyridin-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
Clinical Status
Approved
PubChem CID
9863827
Formula
C21H21N3O3
Canonical SMILES
CC1=CC(=CN=C1NC)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)C
InChI
1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)
InChIKey
XPIJWUTXQAGSLK-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=9863827"></iframe>
3D MOL is unavailable 2D MOL
Physicochemical Properties Molecular Weight 363.4 Topological Polar Surface Area 82.5
XlogP 4.1 Complexity 645
Heavy Atom Count 27 Rotatable Bond Count 4
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 6
Full List of Drug Formulations (DFMs) Containing This API
          Ozenoxacin 10 mg cream Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Benzoic Acid; Octyldodecanol; Peglicol 5 Oleate; Pegoxol 7 Stearate; Propylene Glycol; Purified Water; Stearyl Alcohol
                   Dosage Form Cream
                   Company Biofrontera
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Benzoic acid DIG Info FHA-HIT-interacting protein (Ki = 1.9 nM) [1]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [2]
References
1 WO patent application no. 2017162840A1, SENSITIZATION OF CANCER CELLS TO NAMPT INHIBITORS BY NICOTINIC ACID PHOSPHORIBOSYLTRANSFERASE NEUTRALIZATION.
2 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.